FDA’s Blizzard of Enforcement at Compounding Pharmacies Evident in GMP Warning Letters for FY 2014
This article was originally published in The Gold Sheet
Executive Summary
Inadequate control of contamination – in people, processes and places – was the dominant problem found in the 45 drug GMP warning letters that FDA issued in FY 2014. More than half went to compounding pharmacies.
You may also be interested in...
Investigation Failures, Root Cause Problems Continue To Bedevil Manufacturers
FDA and industry experts discuss avoiding old pitfalls and exploring new investigation models at FDA/PDA conference, as pharmaceutical manufacturers continue to struggle with failure investigations and discerning the root cause of quality defects.
Contamination and Raw Material Testing Issues Raised in FDA Warning Letters
FDA investigators are continuing to find contamination problems and inadequate testing, according to 20 warning letters issued in the first half of 2013, as well as a troubling trend of repeat observations at Baxter, Hospira and Apotex. Observers say to expect more sterility concerns in future warning letters, particularly involving mold, as FDA ramps up GMP enforcement at compounding pharmacies.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”